Screener
Syndax Pharmaceuticals SNDX Business Segments — Other Operating Income Expense Net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,721 | 10,825 |
| Personnel cost and other expenses | 16,701 | 19,082 |
| Other SG&A expenses | 5,140 | 4,412 |
| Stock-based compensation | 12,053 | 10,380 |
| Royalty interest expense | 11,846 | 8,049 |
| Interest expense (income), net | (3,561) | (7,181) |
| Other expense, net | 186 | 221 |
| Segment net loss | $(42,673) | $(84,846) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — other operating income expense net?
- Syndax Pharmaceuticals (SNDX) reported business segments — other operating income expense net of $186K in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — other operating income expense net changed year-over-year?
- Syndax Pharmaceuticals's business segments — other operating income expense net decreased by 15.8% year-over-year, from $221K to $186K.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — other operating income expense net?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — other operating income expense net has grown at a 59.5% compound annual growth rate (CAGR), from $316K to $1.28M.
- What does business segments — other operating income expense net mean?
- This metric captures miscellaneous operating income and expenses that are not directly attributable to core product sales, research, or general administrative functions within the business segment. It includes non-recurring or peripheral items such as gains or losses from asset disposals, legal settlements, or other ancillary operational activities. Tracking this figure allows stakeholders to isolate the impact of non-core events on the segment's operational performance.
Ask your AI about Syndax Pharmaceuticals's business segments — other operating income expense net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude